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Summary: We have established a new chemiluminescent enzyme immunoassay for Carcinoembryonic antigen
(CEA), designated ACCESS CEA, which is adapted to the fully automated ACCESS® immunoassay analyzer. The
assay is based on a one step sandwich-type method using two monoclonal antibodies, one of which is immobilized
on micrometer-size paramagnetic particles and the other is conjugated to alkaline phosphatase. Ten microliters of
calibrators or sera are incubated for 5 minutes at 37 °C with the particles and with the alkaline phosphatase
conjugate. The particles are then magnetically separated and washed to remove unbound components. Time needed
to obtain the first result is less than 15 minutes.
The assay range was 0.04—1000 μg/l of CEA, and the possible high-dose hook effect was prevented at CEA
concentrations up to 100000 μg/l in this working range. The coefficient of variation (CV) for intra-assay precision
was 3.0 to 4.7%, and inter-assay CV was 3.4 to 5.6%. The sample carryover was less than 0.001%. The analytical
recovery ranged from 98 to 104% and a dilution linearity was demonstrated. No interference was detected in any
sample with levels up to 300 mg/1 for bilirubin, 12000 mg/1 for haemoglobin, 50000 mg/1 for human serum albu-
min, 8 500 mg/1 for triacylglycerol, and 500 000 IU/1 for rheumatoid factor. The ACCESS CEA assay also showed
very homogeneous reactivity with purified CEA preparations from different tumours and could discriminate CEA
from four CEA-related normal antigens tested.
Serum samples (n = 362) from patients with malignant or non-malignant disease, as well as from healthy individ-
uals, were analyzed by the ACCESS CEA assay and by the established IMx CEA assay. The CEA values determined
by the ACCESS CEA assay were in good agreement with those determined by the IMx CEA assay, and the
ACCESS CEA assay significantly increased the sensitivity and specificity of tumour diagnosis as compared with
the IMx CEA assay.
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Although various immunoassay systems for CEA are gens (9, 10). Furthermore, these monoclonal antibodies
currently available, the CEA values obtained are highly have been classified into 7 groups (groups A—G) in
variable depending on the assay kit used (3—5). This is light of the domain structure of the CEA molecule
thought to be due to the diverse structures of the carbo- (11, 12). Among them, group F monoclonal antibodies
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group F monoclonal antibody have shown improved
cancer diagnosis (14, 15).
Recent attempts, however, have concentrated on the de-
velopment of automated immunoassay analyzers with
sensitive and precise assay reagents, which also reduce
turn-around time, stuff usage and volume of disposables
and assay costs, and several automated non-isotopic
immunoassay systems have been introduced for estima-
tion of various analytes including CEA (16). Of these,
the ACCESS® immunoassay analyzer (Sanofi Diagnos-
tics Pasteur, Inc., Chaska, MN, USA) is a fully auto-
mated laboratory assay system for enzyme immune-
assays (ElAs) with the term random access relating to
the concept of flexible assay processing and with con-
tinuous access i. e., the ability to interrupt an analyzer
run, add stat or additional routine specimens, and con-
tinue the run with no loss of results (16, 17).
In the present study, by using two defined monoclonal
antibodies, including a .Group F monoclonal antibody,
we tried to establish a new immunoassay for CEA, des-
ignated ACCESS CEA, which is adapted to the fully
automated ACCESS® immunoassay analyzer. We fur-
ther evaluated the ACCESS CEA assay in the CEA de-
terminations of patients' serum samples, and compared
it with the established IMx CEA assay.
Materials and Methods
Carcinoembryonic ant igen and related normal ant igens
Four different CEA preparations, designated CEA-DB, CEA-MY,
CEA-TT, and CEA-TY, were purified from liver metastases from
colorectal carcinomas by treatment with phosphatidylinositol-spe-
cific phospholipase C followed by perchloric acid extraction and
gel filtration as previously described (18). Non-specific cross-react-
ing antigen and non-specific cross-reacting antigen-2 were purified
from pooled normal human lung (19) and meconium (20), respec-
tively. Normal faecal antigen-1 and normal faecal antigen-2 were
obtained from normal adult faeces (21). The non-specific cross-
reacting antigen and normal faecal antigen-1 are partially cross-
reactive with CEA but antigenically unrelated to each other (22).
The purity of each antigen preparation was ensured by the demon-
stration of a single component on immunoelectrophoresis and by
sodium dodecyl sulphate polyacrylamide gel electrophoresis (20,
21), and was also defined by a single NH2-terminal amino acid
(22, 23). The concentrations in weight of all antigens were esti-
mated from the absorption coefficient of each antigen (5).
Monoclonal antibodies
Two mouse anti-CEA monoclonal antibodies (F82-61 and Fll-39)
were prepared as described by Kuroki et al. (10, 12). Both mo-
noclonal antibodies were of IgGl (12). The monoclonal antibodies
were purified from ascitic fluids by ammonium sulphate precipita-
tion and protein A chromatography. Purified monoclonal antibody
F82-61 was immobilized on micrometre-size paramagnetic par-
ticles (Rhone-Poulenc Chimie, Lyon Cedex, France) as capture an-
tibody as described previously (24). The antibody fragment Fab'
of monoclonal antibody Fl 1-39 was prepared with pepsin digestion
followed by gel filtration on a TSK G3000SW column and reduc-
tion with 2-mercaptoethylamine HC1 as described by Hashida et
al. with slight modifications (25), and conjugated to alkaline phos-
phatase (Boehringer Mannheim GmbH, Mannheim, Germany) as
tracer antibody.
I n s t r u m e n t s
The ACCESS® immunoassay analyzer has a unique solid-phase
washing procedure and a chemiluminescent detection system (16,
17). These provide for immunoassays characterized by high sensi-
tivity and/or broad dynamic working ranges. During the wash cy-
cles, magnets are used to pull the paramagnetic particles to the side
of the reaction vessel to allow complete aspiration of the wash
fluid. The particles are resuspended by forcefully adding buffer and
then gently agitating the vessel. The ACCESS system assays use
Lumi-Phos 530 (Lumigen, Inc., Detroit, MI, USA), a dioxetane-
based chemiluminescent substrate, which is dephosphorylated upon
the addition of alkaline phosphatase, resulting in the release of
light. The light emitted is measured by the luminometer and the
system converts the signals (relative luminescence units: RLUs)
into a sample test result.
Commercia l enzyme immunoassay for
carcinoembryonic ant igen
A commercially available EIA kit, Abbott IMx® CEA (Dainabot
Co., Tokyo, Japan), was used for comparative studies. The assay
employed as sandwich-type method with two different monoclonal
antibodies and was performed according to the instructions of the
manufacturer.
Serum samples
Sera from patients with various malignant or benign diseases and
from healthy individuals were collected and stored at -20 °C un-
til use.
Interfer ing substances
Bilirubin, haemoglobin, rheumatoid factor and triacylglycerol were
obtained from International Reagents Corp. (Kobe, Japan); and hu-
man serum albumin from Sigma Chemical Co. (St. Louis, MO,
USA).
Results
Assay protocol obtained
Ten microlitres of calibrators or sera and 40 μΐ of the
diluent are incubated for 5 minutes at 37 °C with 50 μΐ
of monoclonal antibody F82-61-immobilized particles
and with 50 μΐ of monoclonal antibody Fl 1-39 Fab' con-
jugated with alkaline phosphatase. To eliminate interfer-
ence from human anti-mouse immunoglobulin antibody,
the diluent contains 250 mg/1 of Heterophilic Blocking
Reagent (Scantibodies Laboratories, Santee, CA, USA),
which is a mixture of purified mouse IgG subclasses.
After washing the unbound components, 200 μΐ of the
Lumi-Phos® 530 solution are added and the particles are
incubated for 5 minutes at 37 °C. Time needed to obtain
the first result is less than 15 minutes and thereafter one
result is obtained every thirty-six seconds. Results are
interpolated automatically from a previously run stored
standard curve (stable for up to four weeks).
Dose-response curve, detection l imit , and
hook effect
The CEA calibrators with the concentrations ranging
from 0 to 100000 μ^Ι were tested. Figure I represents
a typical dose-response curve in which the luminescence
obtained is plotted against the CEA calibrator concentra-
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Fig. 1 Typical calibration curve obtained by the ACCESS CEA
assay. Note that the first point against the zero calibrator is not
included because of logarithmic scale.
Carryover
The carryover was checked by running a serum sample
spiked with a high amount of CEA (10000 μg/l). After
analyzing 4 replicates of the zero calibrator, 4 replicates
of the sample were then analyzed, as well as 4 replicates
of the zero calibrator. The first replicate of the zero cali-
brator, immediately after the sample, could then be read.
Three values obtained by 3 runs were all < 0.1 μg/l,
indicating that the carryover was less than 0.001%.
Recovery
The recovery of the assay was also determined by spik-
ing known quantities of CEA to 4 different serum sam-
ples, assaying the serum samples and determining the
recovery of the amount added. As shown in table 2, ana-
lytical recovery ranged from 98 to 104%.
tion. The detection limit of the assay, defined as the con-
centration of CEA equivalent to the mean luminescence
plus 2 standard deviations of the zero calibrator, was
calculated based on the respective 10 measurements on
three different instruments and found to be 0.04 μg/l.
Although the dose-response curve extended up to about
10000 μg/l, moderate high-dose hook effect was ob-
served with the concentrations of 50000 and 100000
μg/l (fig. 1). Therefore, the concentrations of calibrators
ranging from 0 to 1000 μg/l were selected for determina-
tion of CEA in serum samples because in this working
range it is virtually impossible to underestimate the con-
centration due to the hook effect except when the con-
centration is extremely high (> 100000 μg/l).
Di lu t ion
Three different serum samples containing elevated con-
centrations of CEA within the assay range were diluted
in the calibrator diluent. The samples and their dilutions
were then assayed to determine linearity on dilution.
Good linearity was observed in each case (fig. 2).
Interference
Assay interference was assessed by measuring the ap-
parent response of the ACCESS CEA assay to various
concentrations of potential interfering substances spiked
into human sera. The basal sera and the spiked serum
samples were then assayed. As shown in table 3, no in-
terference was demonstrated in any sample with levels
Precision study
The intra-assay precision was determined by replication
(n = 20) of three serum samples with different CEA
levels. To assess inter-assay precision, three concentra-
tions of control sera were assayed in duplicate in at least
20 runs over a period of four weeks. As shown in table
1, the intra-assay CV ranged from 3.0 to 4.7%, while
inter-assay CV ranged from 3.4 to 5.6%.
Tab. 1 Intra- and inter-assay precision using control sera.
Intra-assay precision0 Inter-assay precision15
Mean
(μ«Λ)
4.5
46.4
483.4
SD
(ΜβΛ)
0.2
1.4
21.6
CV
(%)
4.7
3.0
4.5
Mean
(μ§/0
5.1
49.0
497.3
SD
(μ§/0
0.2
1.8
27.7
CV
(%)
3.4
3.7
5.6
a
 Three concentrations of control sera were measured (n = 20) in
one assay.
b
 Three concentrations of control sera were measured in duplicate
over four weeks (n = 20 runs).
Tab. 2 Analytical recovery of carcinoembryonic antigen (CEA).
Serum
No.
Endogenous
CEA
(μ§/1)
CEA
spiked
fogfl)
CEA
expected
fogfl)
CEA
measured
(μβ/Ι)
Rec-
overy3
(%)
12.0
45.7
2.5
5.0
7.5
10.0
2.5
5.0
7.5
10.0
14.5
17.0
19.5
22.0
48.2
50.7
53.2
55.7
14.3
16.7
20.0
21.8
48.8
50.9
52.2
56.8
98
98
102
99
101
100
98
102
C 116.5
D 594.3
12.5
25.0
50.0
100.0
25.0
50.0
75.0
100.0
129.0
141.5
166.5
216.5
619.3
644.3
669.3
694.3
133.8
146.9
164.8
215.8
618.0
633.4
659.2
688.7
104
104
99
100
100
98
99
99
a
 The percentage of recovery was defined as the ratio of the CEA
measured divided by the CEA expected, multiplied by 100!
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Fig. 2 Dilution test for the ACCESS CEA assay. Three patients'
sera with CEA values of 28.9 (o), 221.0 (Δ) and 902.0 Mg/l (o)
were diluted with the zero calibrator buffer.
up to 300 mg/1 for bilirubin, 12000 mg/1 for haemoglo-
bin, 50 000 mg/1 for human serum albumin, 8 500 mg/1
for triacylglyerol, or 500000 IU/1 for rheumatoid factor.
Reactivity with carcinoembryonic antigens
and related normal antigens
As shown in figure 3, the ACCESS CEA assay gave no
reaction with non-specific cross-reacting antigen (NCA),
NCA-2, normal faecal antigen (NFA)-L and NFA-2.
Tab. 3 Assay interference
Interference
substance
Bilirubin
Inter-
ference
spiked
(mg/1)
50
150
500
Endo-
genous
CEA
fogfl)
4.1
CEA
measured
Uig/O
4.2
4.0
4.0
Rec-
overy3
(%)
102
98
98
Haemoglobin
Human serum
albumin
Triacylglycerol
Rheumatoid factor
2000
4000
8000
12000
10000
20000
30000
40000
50000
1062
2125
4250
8500
100000b
200000b
300000b
400000b
500000b
4.1
6.2
4.1
6.5
4.1
4.0
3.9
4.1
6.2
6.2
6.2
6.2
6.1
4.3
4.3
4.3
4.2
6.6
6.6
6.7
7.1
100
98
95
100
100
100
100
100
98
105
105
105
102
102
102
103
110
105
Furthermore, the ACCESS CEA assay showed quite
homogeneous reactivity with all CEA preparations
tested (fig. 3).
Normal cutoff level
The normal cutoff level was determined by analyzing
sera from 477 healthy blood donors including smokers
aged from 18 to 82 years, showing the values ranging
from 0.2 to 9.9 μg/l and the average value of 2.03 μg/l.
Since 5 μg/l defined the 95th perceptile in the ACCESS
CEA assay and the kit documentation of the IMx CEA
assay demonstrates a similar distribution of CEA values
in reference populations, we therefore used a tentative
common reference limit of 5 μg/l for both the ACCESS
CEA and the IMx CEA assays.
Clinical evaluat ion of the ACCESS CEA
assay and comparison with a commercial kit
Serum samples of 133 patients with malignant disease
and 72 patients with benign disease as well as of 157
normal subjects were tested with the ACCESS CEA and
IMx CEA assays. The regression analyses of the AC-
CESS CEA assay with the IMx CEA assay showed satis-
factory correlations, although the correlation coefficient
(r) in sera from normal subjects is slightly lower than
those in sera from benign or malignant disease (fig. 4).
However, when frequency of elevated CEA levels for
respective diseases was compared, some differences
were seen between the ACCESS CEA assay and the
IMx CEA assay (tab. 4). It is evident that the total posi-
tive rate for malignant disease showed an definite
increase with the ACCESS CEA assay (56.4%) com-
pared to that of the IMx CEA assay (48.9%). In gastric
cancer, colorectal cancer, lung cancer, and hepatoma,
10000
5 10
Antigen [μρ/Ι]
500 1000
a
 The percentage of recovery was defined as the ratio of the CEA
measured divided by the endogenous CEA, multiplied by 100!b
 IU/1.
Fig. 3 Reactivity of carcinoembryonic antigens (CEAs) and re-
lated normal antigens in the ACCESS CEA assay. Antigens tested·
CEA-DB (*), CEA-MY (a), CEA-TT (A), CEA-TY (o), non-spe-
cific cross-reacting antigen (NCA) (D), NCA-2 (o), normal faecal
antigen (NFA)-l (Δ), and NFA-2 (o). The first point against the
zero calibrator is not included.
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Fig. 4 Correlations of the ACCESS CEA (x) and the IMx CEA
(y) assays, (a) 157 normal subjects, y = 0.952x -1-0.682,
r = 0.812, (b) 72 patients with benign disorder, y=1.047x
prominently increased positive rates were observed with
the ACCESS CEA assay. The total false positive rate
(11.1%) for benign disease with the ACCESS CEA as-
say was certainly lower than that with the IMx CEA
assay (19.4%). Relatively high false positivities with the
IMx CEA assay were observed in sera from patients
with gastric disease, liver disease or diabetes mellitus.
Tab. 4 Positivity of serum CEA in 205 patients with malignant
or benign disease and 157 normal subjects determined with AC-
CESS CEA or IMx CEA.
Diagnosis
Mal ignan t disease
Oesophageal cancer
Gastric cancer
Colorectal cancer
Hepatoma
Pancreatic cancer
Lung cancer
Breast cancer
Cervical cancer
Ovarian cancer
Benign disease
Gastric disease
Chronic gastritis
Gastric ulcer
Gastric polyp
Colorectal disease
Acute colitis
Ulcerative colitis
Crohn's disease
Liver disease
Chronic hepatitis
Liver cirrhosis
Pancreatic disease
Pancreatitis
Uterine disease
Myoma uteri
Diabetes mellitus
No.
of cases
133
10
31
26
14
6
11
20
9
6
72
13
8
3
2
7
2
2
3
34
25
9
2
2
4
4
12
Access®
CEA
>5.0 μg/l
n* (%)
75 (56.4)
4 (40.0)
18(58.1)
17(65.4)
11(78.6)
4 (66.7)
9(81.8)
12 (60.0)
0 (0.0)
0 (0.0)
8(11.1)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
1 (14.3)
1 (50.0)
0 (0.0)
0 (0.0)
3 (8.8)
2 (8.0)
1(11.1)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
4(33.3)
IMx®
CEA
>5.0 μβ/1
η* (%)
65 (48.9)
4 (40.0)
15(48.4)
15(57.7)
7 (50.0)
4 (66.7)
8 (72.7)
12(60.0)
0 (0.0)
0 (0.0)
14(19.4)
4 (30.8)
2(25.0)
1 (33.3)
1 (50.0)
1 (14.3)
1 (50.0)
0 (0.0)
0 (0.0)
4(11.8)
3(12.0)
1(11-1)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
5(41.7)
Normal subjects 157 7 (4.5) 12 (7.6)
Numbers of positives.
+ 0.133, r = 0.962, and (c) 133 patients with malignant disease,
y = 1.001 χ + 1.088, r = 0.995.
In sera from normal individuals, the ACCESS CEA as-
say gave a decreased false positive rate (4.5%) as com-
pared with the IMx CEA assay (7.6%).
Discussion
Group F anti-CEA monoclonal antibodies have been
found to recognize the protein epitopes present on do-
main B3 of the CEA molecule and to discriminate CEA
in tumour tissues from the CEA-related normal antigens
(13). By using a group F monoclonal antibody as tracer
antibody, Kuroki et al. have developed a new radio-
immunoassay and an EIA with increased tumour speci-
ficity and independence from the carbohydrate structure
of the CEA molecule (10, 15). Although those assay
systems revealed improved features in cancer sensitivity
and efficiency in clinical trials (14, 15), it has been im-
possible to employ those assays on the fully automated
immunoassay analyzers. In the present study, by using
two defined monoclonal antibodies with higher specific-
ity and affinity for CEA, we tried to establish a new
immunoassay for CEA, designated ACCESS CEA,
which is adapted to the fully automated ACCESS®
immunoassay analyzer.
The ACCESS CEA assay employed a one step sand-
wich-type method using a combination in which mo-
noclonal antibody F82-61 from group C was used as the
capture and monoclonal antibody F11-39 from group F
as the tracer antibody. Each monoclonal antibody recog-
nizes an epitope present on the N-terminal domain (N)
or C-terminal domain (B3) of the CEA molecule,
respectively (11,12), suggesting that the ACCESS CEA
assay detects only the whole CEA molecules with both
terminal domains.
The assay range of the ACCESS CEA assay was 0.04—
1000 μg/l of CEA and the possible high-dose hook ef-
fect was prevented up to 100000 ^ig/l in the working
range of the assay. The evaluation of assay performance,
such as reproducibility, recovery and dilution tests, and
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interference studies demonstrated the excellent perfor-
mance of the ACCESS CEA assay.
Since many CEA-related antigens have been found in
various tissues unrelated to malignant diseases (1), the
discrimination of CEA from the normal related anti-
gens, especially from normal faecal antigen-2 in nor-
mal adult faeces, seems to be essential for a CEA-
assay system (5). Although non-specific cross-reacting
antigen-2 is a foetal type of CEA (20, 26) and has
not yet been found in any normal tissues or tumour
tissues, the reactivity with this antigen was also tested
in this study. No reactivity of the ACCESS CEA assay
with NCA, NFA-1, NFA-2, and NCA-2 indicates that
this assay system is able to distinguish CEA from the
related normal antigens.
The independence of a CEA-assay system from the in-
fluence of variations in the sugar chains of the CEA
molecule also seems to be very important, because ap-
parent variation in CEA determination appeared to be
mainly due to variation in the structures of carbohydrate
chains (8). Furthermore, the expression of epitopes on
the sugar chains of the CEA molecule is changeable dur-
ing synthesis and secretion of CEA by tumour cells, and
thus is unstable during the course of malignancy (27).
This may result in false apparent fluctuations of the
CEA level in the course of diseases unless the assay
system is independent of carbohydrate epitopes. The
ACCESS CEA assay showed quite homogeneous reac-
tivity with different CEA preparations tested, showing
its independence from the effect of variations in the
sugar chains of the CEA molecule.
Since the ACCESS CEA assay certainly showed im-
proved features with respect to the reactivities with puri-
fied CEA and related antigen preparations and exhibited
excellent assay performance, the clinical features of the
ACCESS CEA assay, compared with those of the IMx
CEA assay, were estimated in this study. For a fair com-
parison, the same 362 serum samples from patients with
malignant or non-malignant disease, as well as from
healthy individuals, were simultaneously assayed by the
ACCESS CEA and the IMx CEA assays. The improved
diagnostic sensitivity of the ACCESS CEA assay is de-
monstrated in table 4. In comparison with the IMx
CEA assay, 7.5% increases in the diagnostic sensitivity
were observed with the ACCESS CEA assay. This
was not simply due to an unsuitable cutoff level in
the ACCESS CEA assay since the false positive rate
with this assay in benign disease or normal subjects
was less than that of the IMx CEA assay; that is, the
diagnostic specificity (93.4%, 214/229 cases) with the
ACCESS CEA assay was also better than that (88.6%,
203/229 cases) with the IMx CEA assay. The ACCESS
CEA assay, however, deserves further evaluation using
longitudinal collected serum samples from cancer pa-
tients to determine how well CEA levels correlate
with clinical course.
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